Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates

FEBS Open Bio

Volumn 6, Issue 10, 2016, Pages 1008-1015

  Deushi, Michiyo ^a   Osaka, Mizuko ^a   Nakano, Kaku ^b   Osada, Kyoichi ^c   Egashira, Kensuke ^b   Yoshida, Masayuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c MEIJI UNIVERSITY   (Japan)

Author keywords

dietary oxysterols; ezetimibe; Niemann Pick C1 like1; nonalcoholic fatty liver disease; nonhuman primate; steatosis

Indexed keywords

CHOLESTEROL; EZETIMIBE; LIPOPROTEIN; OXYSTEROL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CONTROLLED STUDY; DYSLIPIDEMIA; FATTY LIVER; HYPERCHOLESTEROLEMIA; INFLAMMATION; INFLAMMATORY CELL; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; MACACA FASCICULARIS; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84988384559     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1002/2211-5463.12107     Document Type: Article

References (24)

1. Lake RJ and Scholes P (1997) Quality and consumption of oxidized lipids from deep-frying fats and oils in New Zealand. J Am Oil Chem Soc 74, 1065–10681.
2. Lake RJ and Scholes P (1997) Consumption of cholesterol oxides from fast foods fried in beef fat in New Zealand. J Am Oil Chem Soc 74, 1069–1075.
3. Poli G, Biasi F and Leonarduzzi G (2013) Oxysterols in the pathogenesis of major chronic diseases. Redox Biol 1, 125–130.
4. Sato K, Nakano K, Katsuki S, Matoba T, Osada K, Sawamura T, Sunagawa K and Egashira K (2012) Dietary cholesterol oxidation products accelerate plaque destabilization and rupture associated with monocyte infiltration/activation via the MCP-1-CCR2 pathway in mouse brachiocephalic arteries: therapeutic effects of ezetimibe. J Atheroscler Thromb 19, 986–998.
5. Argo CK, Northup PG, Al-Osaimi AM and Caldwell SH (2009) Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 51, 371–379.
6. Marí M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC and García-Ruiz C (2006) Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 4, 185–198.
7. Terunuma S, Kumata N and Osada K (2013) Ezetimibe impairs uptake of dietary cholesterol oxidation products and reduces alterations in hepatic cholesterol metabolism and antioxidant function in rats. Lipids 48, 587–595.
8. Bergen WG and Mersmann HJ (2005) Comparative aspects of lipid metabolism: impact on contemporary research and use of animal models. J Nutr 135, 2499–2502.
9. Davis Jr HR, Compton DS, Hoos L and Tetzloff G (2001) Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 21, 2032–2038.
10. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, Ishii H and Yoshida M (2007) Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 581, 5664–5670.
11. Osada K, Kodama T, Noda S, Yamada K and Sugano M (1995) Oxidized cholesterol modulates age-related change in lipid metabolism in rats. Lipids 30, 405–413.
12. Usui S, Hara Y, Hosaki S and Okazaki M (2002) A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 43, 805–814.
13. Folch J, Ascoli I, Meath JA, Lebaron FN and Stanlay GHS (1951) Preparation of lipide extracts from brain tissue. J Biol Chem 191, 833–841.
14. Richmond W (1973) Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem 19, 1350–1356.
15. Spayd RW, Bruschi B, Burdick BA, Dappen GM, Eikenberry JN, Esders TW, Figueras J, Goodhue CT, LaRossa DD, Nelson RW et al. (1978) Multilayer film elements for clinical analysis: applications to representative chemical determinations. Clin Chem 24, 1343.
16. Takano Y, Shimokado K, Hata Y and Yoshida M (2007) HIV envelope protein gp120-triggered CD4+ T-cell adhesion to vascular endothelium is regulated via CD4 and CXCR4 receptors. Biochem Biophys Acta 1772, 549–555.
17. Schaffner F and Thaler HH (1986) Nonalcoholic fatty liver disease. Prog Liver Dis 8, 283–298.
18. Osada K, Sasaki E and Sugano M (1994) Inhibition of cholesterol absorption by oxidized cholesterol in rats. Biosci Biotech Biochem 58, 782–783.
19. Schroepfer Jr GJ (2000) Oxysterols: modulators of cholesterol metabolism and other processes. Physiol Rev 80, 361–554.
20. Obstfeld AE, Sugaru E, Thearle M, Francisco AM, Gayet C, Ginsberg HN, Ables EV and Ferrante Jr AW (2010) C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes 59, 916–925.
21. Shimamura T, Fujisawa T, Husain RS, Kioi M, Nakajima A and Puri KR (2008) Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. J Immunol 181, 4656–4665.
22. Sugizaki T, Watanabe M, Horai Y, Kaneko-Iwasaki N, Arita E, Miyazaki T, Morimoto K, Honda A, Irie J and Itoh H (2014) The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice. Endocrinology 155, 2810–2819.
23. Brown AJ and Jessup W (1999) Oxysterols and atherosclerosis. Atherosclerosis 142, 1–28.
24. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K and Wakasa K (2002) In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 37, 56–62.